MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijcrp.2026.200701

Медицинская библиотека · International journal of cardiology. Cardiovascular risk and prevention · 2026

Gaps and disparities in Lp(a) testing before universal screening: A 10-year analysis.

Patel Hemchandra B, Bawahab Yahya, Vasile Vlad C

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD), yet testing remains underutilized. Updated guidance now recommends once-per-lifetime Lp(a) testing in all individuals. We evaluated Lp(a) testing utilization from 2016 to 2025, to identify gaps, disparities and overall trends in testing utilization.

METHODS

Retrospective cohort study of lipid-tested patients from 2016 to 2025. Lp(a) testing rates were calculated among lipid-tested patients. Multivariable logistic regression identified predictors of testing, and interrupted time-series (ITS) was used to assess trends in testing rates.

RESULTS

Among 1,009,102 lipid-tested patients, 75,021 (7.4%) underwent Lp(a) testing; 80.9% for primary prevention, 55% male. Males were more likely to be tested (OR 1.24, 95% CI 1.22-1.26). ASCVD was an independent predictor for testing (OR 1.38, 95% CI 1.35-1.41), driven by coronary artery disease alone (OR 1.74); while other ASCVD subtypes were associated with decreased odds of testing. Age was also predictive of Lp(a) test (OR 1.06 per 10 years, 95% CI 1.05-1.06). ITS revealed an immediate 58.8% increase at Q4 2021 (IRR = 1.588, 95% CI: 1.047-2.409), with a sustained 3.1% quarterly increase thereafter (IRR = 1.031, 95% CI: 1.008-1.056).

CONCLUSIONS

Lp(a) testing has substantially grown over the past decade, however important gaps and disparities in testing utilization were identified. Males are tested more frequently than females, individuals with non-CAD ASCVD subtypes are less likely to be tested, and testing preferentially reaches older patients. With updated guidance, future efforts must prioritize broader testing adoption, while addressing gaps in utilization.

Для цитирования: Patel Hemchandra B, Bawahab Yahya, Vasile Vlad C. Gaps and disparities in Lp(a) testing before universal screening: A 10-year analysis.. International journal of cardiology. Cardiovascular risk and prevention. 2026. DOI: 10.1016/j.ijcrp.2026.200701.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.